KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Net Margin (2016 - 2025)

Historic Net Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 31.34%.

  • Halozyme Therapeutics' Net Margin fell 773200.0% to 31.34% in Q4 2025 from the same period last year, while for Dec 2025 it was 22.69%, marking a year-over-year decrease of 210500.0%. This contributed to the annual value of 22.69% for FY2025, which is 210500.0% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Net Margin stood at 31.34% for Q4 2025, which was down 773200.0% from 49.46% recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Net Margin registered a high of 186.99% during Q3 2021, and its lowest value of 31.34% during Q4 2025.
  • Moreover, its 5-year median value for Net Margin was 39.76% (2024), whereas its average is 44.88%.
  • In the last 5 years, Halozyme Therapeutics' Net Margin surged by 1315500bps in 2021 and then plummeted by -1574900bps in 2022.
  • Halozyme Therapeutics' Net Margin (Quarter) stood at 65.46% in 2021, then crashed by -51bps to 31.79% in 2022, then increased by 17bps to 37.12% in 2023, then rose by 24bps to 45.98% in 2024, then tumbled by -168bps to 31.34% in 2025.
  • Its last three reported values are 31.34% in Q4 2025, 49.46% for Q3 2025, and 50.7% during Q2 2025.